Session to detail torcetrapib's stunning failure

There's lots of anticipation building for the ACC meeting in New Orleans. One of the most closely-watched presentations will detail how torcetrapib failed a trial that experts in the field had widely expected to demonstrate positive efficacy rates. Data on torcetrapib's fatal flaw in raising blood pressure will be forthcoming. Analysts expect that the numbers may shed considerable light on the prospect of other CTEP inhibitors being developed by Roche and Merck. Torcetrapib had demonstrated its effectiveness in raising HDL, an approach that is expected to deliver a key new weapon against heart disease. It had been widely touted as a prospective blockbuster.

- read the report on the upcoming gathering from Newsweek

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.